- In April 2023, Pfizer Inc. announced the expansion of its oncology pipeline through a strategic partnership with Arvinas, Inc. The collaboration focuses on the co-development of novel protein degrader therapies targeting difficult-to-treat cancers. This initiative emphasizes Pfizer’s commitment to advancing ethical pharmaceuticals by investing in innovative, precision-based treatment solutions to address unmet medical needs in oncology
- In March 2023, AstraZeneca Plc launched its Sustainable Markets Initiative Health Systems Task Force pilot program across several low- and middle-income countries. The program aims to improve access to ethical medicines through more efficient supply chain models and public-private collaborations. The initiative underlines AstraZeneca's dedication to equitable healthcare and its leadership role in delivering high-standard prescription treatments globally
- In February 2023, Johnson & Johnson's Janssen Pharmaceuticals received FDA approval for its new ethical prescription therapy, Tepmetko, indicated for patients with metastatic non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping alterations. This approval marks a significant milestone in personalized oncology treatments, reinforcing the company’s role in delivering clinically validated, targeted therapies under strict regulatory compliance
- In February 2023, Novartis AG partnered with the African Medical Supplies Platform (AMSP) to enhance the availability of branded cardiovascular and diabetes medications across sub-Saharan Africa. The agreement supports Novartis' ethical drug distribution initiatives and aims to reduce disease burden in underserved regions through affordable access to essential, high-quality medications
- In January 2023, Merck & Co., Inc. launched a global access program for its immunotherapy drug Keytruda, aiming to increase affordability and accessibility in low-income countries. This development reflects Merck’s ongoing commitment to expanding global access to cutting-edge ethical pharmaceuticals, particularly in oncology, while maintaining the highest standards of safety, efficacy, and patient-centric innovation
